Nurix Therapeutics Chief Scientific Officer Gwenn Hansen Reports Disposal of $142,900.9987 in Common Shares
Bitget2026/11/03 00:43- Nurix Therapeutics Chief Scientific Officer Gwenn Hansen sold 3,957 common shares at $26.2791 on Oct. 30, 2026.
- Hansen also acquired 10,182 common shares at $0 through restricted stock unit conversions on Oct. 30.
- On Nov. 2, 2026, Hansen exercised options for 1,452 shares at $1.86, selling those shares at $26.8.
- Direct beneficial ownership stood at 123,452 common shares following the transactions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Crypto prices
More
